(US), a publicly traded pharmaceutical company. Prior to joining Millennium,
from 1986 to 1994 Mr. Holtzman was a founder and Executive Vice President of
DNX Corporation, a publicly-traded biotechnology company. In addition to his
role at Infinity, he is currently a member of the Board of Directors of
Anadys Pharmaceuticals, Inc. (US) and Sartori Pharmaceuticals, Inc. (US). Mr.
Holtzman graduated from Michigan State University and received his B.Phil.
from Oxford University, which he attended as a Rhodes Scholar.
Francois Meyer, Ph.D.
Francois Meyer was General Director for Research and Development at
Aventis Pharma, France until 2002 and subsequently Director-General of
Aventis' Gene Therapy Division, Gencell, until his retirement in 2006. He
joined Gencell as Vice-President in 1996, within the Rhone-Poulenc Group,
prior to the formation of Aventis when Rhone-Poulenc merged with Hoechst. He
was promoted to Vice President of RPR Global Research in 1997, and Corporate
Senior Vice President of Global Research in 1998. In 1992, Dr. Meyer joined
Sandoz Pharma's gene and cell therapy business as Vice President, while he
also served as a member of the company's Corporate Research Board. From 1989
to 1992, he was Director of Research at the CNRS. From 1980 - 1984, he built
and headed the Molecular Genetics department in the newly formed
Biotechnology division at Ciba-Geigy, where he was responsible for the
discovery and production of new recombinant proteins.
Dr. Meyer is a member of the Board of Directors of BioSeek, Inc. (US),
Introgen Therapeutics, Inc. (US), Gene Therapy, Inc. (US), and Urogene SA
(France), and a member of the Scientific Advisory Boards of Genethon
(France), Systemix, Inc. (US) and Biotransplant, Inc. (US). Dr. Meyer
graduated from the Swiss Federal Institute of Technology (ETFH), in Zurich,
and studied Biochemistry and Molecular Biology at the University of Zurich.
He received his Ph.D. from the Institute for Molecular Biology
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2010 PR Newswire.
All rights reserved
. Clinical Laboratory Management Associations ThinkLab 10 Surpasses Attendance Goals2
. NACVSA Points out Perils of Polygraph: Killer Passes Polygraph, Innocent Man Fails, Killer Goes On To Kill Again3
. New Promega Maxwell 16 LEV Blood DNA Kit Surpasses Concentration Standards in Less Time4
. NACVSA: Killer of Five Teenagers Passes Polygraph 5
. Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years6
. MedTrust Online Surpasses 5,000 Registered Users and Adds Dr. Henry Friedman to Oncology Advisory Board7
. New Vision Device Passes Virtual Collision Test for People with Tunnel Vision8
. OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance9
. China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification10
. Eklin Medical Surpasses 1,000th RapidStudy(R) Digital Radiography System Installation Featuring Canon DR Technology11
. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™